Soo Bandhigida Daaweynta CAR T-cell ee Singapore – a groundbreaking and revolutionary approach to cancer treatment. The National University Cancer Institute, Singapore (NCIS) has developed an innovative therapy that uses the immune system to fight cancer. Unlike traditional chemotherapy, CAR T Cell Therapy is customized, using the modification of a patient’s own blood cells to specifically target and eliminate cancer cells. The use of gamma-delta T cells from healthy donors improves the quality of CAR-T cells while potentially cutting treatment costs, making this therapy even more attractive. This method, developed by CytoMed Therapeutics, represents a substantial advancement in the area. The Health Sciences Authority has approved a phase 1 clinical trial that will recruit healthy blood donors for testing and patients with resistant advanced cancers for treatment. This non-personalized yet effective strategy has the potential to improve cancer care in Singapore, providing hope and new opportunities for patients and their families.
CAR T-Cell Therapy gudaha Singapore - Xaalada Hadda
CAR-T cell therapy has become a game-changer in the way cancer is treated, and Singapore is very excited about this new therapy. Singapore has made a lot of progress in adopting CAR-T cell therapy through tijaabada caafimaadka, iskaashiga, iyo taageerada sharciyeed. Tani waxay caawisay bukaanada waxayna gacan ka gaysatay horumarinta daryeelka kansarka. Singapore wali waxay ku jirtaa meesha ugu sareysa daawaynta unugyada CAR-T sababtoo ah waxay sii wadaysaa samaynta cilmi baarista waxayna leedahay nidaam daryeel caafimaad oo wanaagsan. Daaweynta T-Cell-ka Baabuurka gudaha Singapore wuxuu helay xawaare, isagoo rajo siinaya bukaannada kansarka iyo qoysaskooda.
Iyadoo tiro tijaabo caafimaad ah ay ka dhacayaan Isbitaalka Jaamacadda Qaranka, Singapore, Chimeric Agent Receptor (CAR) T-cell therapy is developing at a very fast pace in Singapore. Oscar Saxelby-Lee suffers from Lymphoblastic lymphoblastic leukemia, a disease that has resisted all treatments. The five-year-old from the United Kingdom is in Singapore for a procedure that has never been given to one other infant on the planet. The boy flew in from Worcester, England, for a new type of therapy that involves drawing immune cells from a patient’s blood and implanting them with a Chimeric Antigen Receptor (CAR-T).
Maamulka Sayniska Caafimaadka ee Singapore (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue, and gene therapy products (CTGTP) regulatory framework. HSA approved Kymriah for the treatment of pediatric and young adult patients from 2 to 25 years of age with B-cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell qanjiro (DLBCL) after two or more lines of systemic therapy.
Soo-dhoweeyuhu wuxuu ku xidhan yahay borotiin gaar ah oo ku jira unugyada kansarka, taasoo keenta unugyada CAR-T inay hawl galiyaan oo burburiyaan unugyada kansarka. Maaddaama unugyadu leukemia-yadu ay la mid yihiin habka difaaca Oscar, qaabkan daawaynta CAR-T waa mid gaar ah oo aad u adag, sida uu qabo Associate Professor Allen Yeoh, madaxa kansarka carruurta ee Isbitaalka Jaamacadda Qaranka (NUH). Oscar ayaa noqon doona bini'aadmigii labaad ee aduunka ee mara nidaamkan. Ilmihii ugu horreeyay ayaa lagu daweeyay NUUX dhawr sano ka dib.
Daawaynta unugyada CAR-T waa nooc cusub oo dawo ah oo wax ka beddelay habka dadka adduunka oo dhan u daweeyaan kansarka. Singapore, oo caan ku ah nidaamka daryeelka caafimaadka ee tignoolajiyada sare iyo kaabayaasha cilmi baarista, waxay ahayd mid ka mid ah meelaha ugu horreeya ee la aqbalo oo la isticmaalo daaweynta unugyada CAR-T. Qaybtan, waxaan kaga hadli doonaa meesha daawaynta unugyada CAR-T ay hadda ku taal Singapore iyo sida ay u saamayso bukaanka kansarka.
Iyada oo loo marayo daraasado caafimaad oo kala duwan, daaweynta unugyada CAR-T waxay horumar badan ka samaysay Singapore. Noocyada kala duwan ee kansarka, sida leukemia, lymphoma, iyo burooyinka adag, ayaa ahaa diiradda daraasaddan. Natiijadu waxay ahaayeen kuwo dhiirigelin leh, oo muujinaya heerar sare oo jawaab celin ah iyo waqtiyo dheer oo cafis ah. Natiijooyinka wanaagsan ayaa u suurtageliyay maamulayaasha si ay u ansixiyaan daaweynta unugyada CAR-T, taas oo macnaheedu yahay hadda waxaa loo isticmaali karaa waxqabadka kiliinikada.
Daawaynta unugyada CAR-T waxa si weyn loo isticmaali doonaa oo keliya haddii ay fududahay in la helo oo aanay kharash badan ku bixi doonin. Singapore waxay qaaday tillaabooyin ay ku hubinayso in dadku ay heli karaan daawayntan cusub. Si wadajir ah hay'adaha daryeelka caafimaadka, Wasaaradda Caafimaadku waxay ka shaqeysay abuurista hab-raacyo iyo nidaamyo lacag-bixineed si ay ugu fududaato bukaannada inay helaan daawaynta unugyada CAR-T.
Nidaamka deegaanka ee daryeelka caafimaadka ee Singapore wuxuu xooga saarayaa iskaashiga ka dhexeeya shaqaalaha daryeelka caafimaadka, aqoonyahannada, iyo ganacsiyada. Singabuur waxa ay awooday in ay ka qayb qaadato daraasaadka daawaynta unug ee caalamiga ah ee CAR-T iyada oo ay ugu mahad celinayso wada shaqaynta ay la leedahay shirkadaha ugu sareeya ee biopharmaceutical ee aduunka. Heshiisyada noocaan ah waxay dardar galiyeen cilmi-baarista, waxay sameeyeen daawaynta mid waxtar leh, waxayna siiyeen dad badan inay helaan daawayn heersare ah.
Waa maxay Unugyada CAR-T iyo sidee bay u burburiyaan unugyada kansarka?
CAR T cells, also known as Chimeric Antigen Receptor T cells, are immune cells that play an important part in CAR T Cell Therapy. These specialized T cells are engineered in a laboratory to express a chimeric antigen receptor on their surface. CAR T cells, also known as Chimeric Antigen Receptor T cells, are immune cells that play an important part in CAR T Cell Therapy. In a laboratory, these specialized T cells are designed to express a chimeric antigen receptor on their surface. This receptor is programmed to recognize specific proteins on the surface of cancer cells known as antigens. When the CAR T cells are identified by the immune system, they bind to the cancer cells, triggering a robust immune response. Unugyada CAR T that have been activated grow and launch a targeted attack on cancer cells, effectively destroying them.
Xaaladdee ayaa lagu daweyn karaa daawaynta unugyada CAR T gudaha Singapore?
CAR T Cell Therapy is a kind of advanced immunotherapy that has shown significant effectiveness in treating specific conditions, particularly targeting patients facing challenging scenarios. This advanced therapy is particularly well-suited for individuals diagnosed with relapsed aggressive forms of Acute Lymphoblastic Leukemia (ALL), multiple myeloma, and cases of relapse in Non-Hodgkin Lymphoma, such as Diffuse Large B-cell Lymphoma (DLBCL). This is especially important when traditional treatments have failed and at least two past treatment approaches have proven ineffective in reaching the desired results. Thus, CAR T-Cell Therapy emerges as a promising therapy option for patients suffering from leukemia and lymphoma, providing them a beacon of hope and the promise for improved treatment outcomes in Singapore.
Habka Fudud ee Helitaanka Daaweynta Unug ee CAR T
Soo dir warbixinnadaada
U dir iimayl info@cancerfax.com oo leh taariikhdaada caafimaad iyo diiwaanadaada, oo ay ku jiraan baaritaanada dhiiga iyo baarista. Tani waxay naga caawineysaa inaan qiimeyno xaaladaada oo aan kugu hago daaweynta kansarka ugu habboon.
Qiimaynta & Ra'yiga
Waxaan kaa caawin doonaa inaad hesho fiisaha caafimaadka oo aan u diyaarino qorshayaashaada safarka si aan u hubinno safarka fudud ee aad uga soo kabato cudurkan.
Fiisaha caafimaadka iyo safarka
Shaqaalaheenna khibradda leh ayaa si fiican u qiimeyn doona warbixinnadaada waxayna ku siin doonaan baaritaan dhammaystiran iyo talo khabiir oo ku talinaya isbitaallo iyo takhasusyo ku habboon.
Daawaynta & dabagalka
Kooxdayada daacadda ah ayaa sii wadi doona inay ku weheliyaan inta lagu jiro nidaamka daawaynta markaad timaaddo cisbitaalka aad doorbidayso.
Maxaad Singapore ugu doorataa daaweynta CAR T-cell?
Kaabayaasha Caafimaadka Sare
Singapore waxa ay caan ku tahay tignoolajiyada casriga ah iyo tas-hiilaad caafimaad oo heer caalami ah. Dawladdu waxay gelisay lacag aad u badan daryeelka caafimaadka waxayna leedahay nidaam xooggan oo heer caalami ah. Sannadkii 2010, WHO ayaa nidaamka daryeelka caafimaadka Singapore ka dhigtay kaalinta lixaad 100 ka ugu wanaagsan adduunka. Waqtigan xaadirka ah, 22 cosbitaal iyo tas-hiilaad caafimaad oo kale oo ku yaal Singapore waxaa ansixiyay Guddiga Wadajirka ah ee Caalamiga ah (JCI).
Xirfadlayaal Caafimaad oo Xirfad sare leh
Singapore waxay leedahay dhakhaatiir aad u xirfad sare leh oo khibrad leh, oo ay ku jiraan dhakhaatiirta kansarka iyo dhakhaatiirta dhiigga ee ku takhasusay daaweynta unugyada CAR-T. Dhakhaatiirtan ayaa lagu soo tababaray gudaha Maraykanka iyo dibadda, qaar badan oo ka mid ahina waxay ka soo shaqeeyeen ama wax ku soo barteen machadyo caafimaad oo si weyn looga yaqaano dalka dibadiisa.
Xeerarka Adag iyo Xakamaynta Tayada
Ganacsiga daryeelka caafimaadka ee Singapore waxaa gacanta ku haya sharciyo adag iyo hubinta tayada. Saraakiisha caafimaadka ee dalka, sida Maamulka Sayniska Caafimaadka (HSA), waxay hubiyaan in daawaynta, sida daawaynta unugga CAR-T, ay la kulmaan heerarka adag ee badbaadada iyo waxtarka. Tani waxay siinaysaa bukaanada ajnabiga ah ee raba inay ka helaan daawaynta Singapore xasilooni maskaxeed.
Dhaqamada Kala Duwan Iyo Deegaanka Ingiriisiga Ku Hadla
Singapore waa magaalo leh dhaqamo iyo dad badan oo kala duwan, Ingiriisiguna waa mid ka mid ah luqadaha la aqoonsan yahay. Tani waxay ka dhigaysaa meel fiican oo loogu talagalay bukaannada ajnabiga ah inay aadaan sababtoo ah isgaarsiintu waa sahlan tahay oo degdeg ah. Bukaanada ka yimid wadamada kale waxay si sahal ah ula hadli karaan dhakhaatiirtooda, baran karaan ikhtiyaarkooda daawaynta, iyo in la daryeelo walaacooda caafimaad.
Habka Daawaynta ee CAR-T Therapy Cell
Habka Daawaynta Unugyada CAR-T waxay ka kooban tahay marxaladaha waaweyn ee soo socda:
La-tashiga bilowga ah:
Bukaanka qaba kansarka waa inuu la tashadaa dhakhtarka kansarka si uu ugala hadlo u-qalmitaanka CAR-T Therapy Cell.
Qiimaynta ka dib, bukaanka ayaa loo sheegi doonaa khatarta daawaynta, faa'iidooyinka, iyo waxa laga filayo.
Ururinta Unugyada iyo Wax ka beddelka:
Unugyada T waxaa laga soo ururiyaa bukaanka hab la mid ah ku-deeqidda dhiigga ee loo yaqaan apheresis.
Unugyadan T waxa lagu farsameeyay hidde ahaan shaybaadhka si ay u muujiyaan reseptors-ka antigen-ka (CAR).
Unugyada wax laga beddelay waa la dhaqameeyey oo la dhuftey si ay u abuuraan tiro ku filan oo ah unugyada CAR T.
Habka faleebo:
Si loo abuuro jawi ku habboon dhaqdhaqaaqa unugyada CAR T, bukaanku wuxuu maraa hab qaboojin, kaas oo caadi ahaan ku lug leh kiimoterabi-yar.
Unugyada CAR T ee la beddelay ayaa markaa dib loogu geliyaa dhiigga bukaanka.
Unugyada CAR T waxay ku wareegaan jirka, iyagoo aqoonsanaya oo ku xiran unugyada kansarka oo muujinaya antigens gaar ah.
Dabagalka iyo Dabagalka:
Ka dib habka faleebada oo dhan, bukaanka si dhow ayaa loola socon doonaa saameynaha soo raaca iyo jawaabta daaweynta.
Ballamaha daba-galka ah ayaa si joogto ah loo qorsheeyey si loo hubiyo waxtarka daawaynta oo loo xalliyo wixii welwel ah ee soo koraya.
Korjoogteynta muddada-dheer waxay hubisaa natiijooyin faa'iido leh waxayna wax ka qabtaa arrimaha suurtagalka ah ee bukaannada kansarka.
Waa maxay Qiimaha Daawaynta Unug ee CAR T ee Singapore?
Kymriah CAR T-cell therapy, kaas oo Golaha Caafimaadka ee Singapore u ansixiyay daawaynta bararka waaweyn ee B-cell lymfoma iyo B-cell lymphoblastic leukemia ba'an, waxay ku kici kartaa ilaa $ 475,000 USD ie ku dhawaad $ 700,000 SGD.
CAR T-Cell Khabiirada Ku-daweynta Unugyada ee Singapore
Qaado ra'yi labaad oo khabiir ah oo ku saabsan faleebo daawaynta CAR T-cell oo ka timid khabiirada ugu fiican Singapore.
Dr. Ang Peng Tiam (MD, MRCP, FAMS, FACP)
DARYEELKA CAAFIMAADKA
Profile: Agaasimaha caafimaadka iyo la taliye sare oo ka tirsan xarunta kansarka ee Parkway ee qaybta kansarka. Dr Ang waa xubin golaha ka tirsan Singapore Cancer Society. Wuxuu sidoo kale ahaa Madaxweynihii hore ee Singapore Society of Oncology.
Profile: Dr Colin waxa uu shahaadadiisa caafimaad ka qaatay Jaamacadda Qaranka ee Ireland 2002dii ka dibna waxa uu dhammaystay degenaanshaha daawaynta gudaha iyo tabobar takhasuska Hematology ee Cisbitaalka Guud ee Singapore.
Profile: Dr Colin waxa uu shahaadadiisa caafimaad ka qaatay Jaamacadda Qaranka ee Ireland 2002dii ka dibna waxa uu dhammaystay degenaanshaha daawaynta gudaha iyo tabobar takhasuska Hematology ee Cisbitaalka Guud ee Singapore.
Cisbitaalada ugu Sareeya ee CAR T-Cell Therapy ee Singapore
Parkway Cancer Center
Kuwa cusub immunotherapy Habka loo yaqaan CAR T-cell therapy waxay muujisay ballanqaad aan caadi ahayn oo ku saabsan daaweynta noocyo kala duwan oo malignancies ah. Beijing, Cusbitaalka Kansarka ee Jaamacadda Peking ee Shiinaha ayaa noqday hormuudka caalamiga ah ee horumarinta daaweynta CAR T-cell. Iyaga oo gacan ka helaya kooxdooda cilmi-nafsiyeedka badan, oo ka kooban dhakhaatiirta kansarka, dhakhaatiirta difaaca jirka, iyo hidde-yaqaannada, daaweynta kansarka shakhsi ahaaneed ayaa si weyn u horumartay. Cisbitaalka Kansarka ee Jaamacadda Peking ayaa natiijooyin fiican ka helay bukaannada qaba cudurrada dhiigbaxa iyagoo beddelaya unugyada T ee bukaannada si ay u muujiyaan reseptors-ka antigen-ka (CARs). Daaweyntani waxay siinaysaa bukaanada kansarka rajo cusub iyo sare u qaadida heerka badbaadada.
Faa'iidada ugu weyni waa in daawaynta CAR T-cell ay u baahan tahay faleebo keliya oo badanaa waxay u baahan tahay laba toddobaad oo keliya daryeelka bukaan-jiifka. Bukaannada qaba lymphoma non-Hodgkin iyo leukemia carruurta ee hadda la helay, dhanka kale, waxay caadi ahaan u baahan yihiin. chemotherapy ugu yaraan lix bilood ama ka badan.
Faa'iidooyinka daaweynta CAR T-cell, oo ah dawo nool, waxay sii jiri kartaa sanado badan. Haddi iyo marka ay soo noqodku dhacdo, unugyadu wali way awoodi doonaan inay aqoonsadaan oo ay beegsadaan unugyada kansarka sababtoo ah waxay ku noolaan karaan jidhka muddo dheer.
Inkasta oo macluumaadka uu weli soo korayo, 42% bukaannada lymphoma ee qaangaarka ah ee lagu sameeyay daawaynta CD19 CAR T-cell ayaa weli ku jira cafis 15 bilood ka dib. Lix bilood ka dib, saddex-meelood laba meel bukaannada qaba kansarka leukemia ee ba'an ee carruurta ayaa weli ku jiray cafis. Nasiib darro, bukaannadani waxay lahaayeen burooyin aad u daran kuwaas oo aan si guul leh loo daweyn iyadoo la adeegsanayo heerarka daryeelka dhaqameed.
Patients between the ages of 3 Years to 70 Years have tried CAR T-Cell therapy for different types of kansarka dhiigga and is very effective. Many centers have claimed success rates of more than 80%. The optimum candidate for CAR T-cell therapy at this time is a juvenile with acute lymphoblastic leukemia or an adult with severe B-cell lymphoma who has already had two lines of ineffective therapy.
Ka hor dhamaadka 2017, ma jirin heer la aqbalay daryeelka bukaanka kuwaas oo horay u soo maray laba xariiq oo daawaynta ah iyada oo aan la kulmin cafis. Daawaynta kaliya ee FDA-ansixisay ee ilaa hadda la caddeeyey inay faa'iido weyn u leedahay bukaankan waa daawaynta CAR T-cell.
Mid ka mid ah waxyaabaha ugu wanaagsan ee ku saabsan daaweynta CAR T-cell waa inay beegsato unugyada saxda ah. Qabayaasha CAR ee lagu daray unugyada T waxay heli karaan calaamado gaar ah unugyada kansarka. Tani waxay suurtogal ka dhigaysaa in la bixiyo daawaynta la beegsaday. Habkan la beegsanayo waxa ay wax u dhimaysaa unugyada caafimaadka qaba sida ugu yar ee suurtogalka ah waxana ay hoos u dhigtaa halista waxyeelooyinka ka yimaada daawaynta dhaqameed sida kiimoterabiga.
Laakiin waxaa muhiim ah in maskaxda lagu hayo in daawaynta CAR T-cell ay wali tahay aag cusub oo wali isbedelaysa. Cilmi-baarayaasha iyo takhaatiirta ayaa si adag u shaqeynaya si ay u xalliyaan dhibaatooyinka sida kharashka badan, suurtagalnimada waxyeellooyin halis ah, iyo xaqiiqda ah in ay u shaqeyso oo kaliya noocyada kansarka qaarkood.
Dhammaadkii, daawaynta CAR T-cell waxay muujisay inay tahay hab aad loogu guulaysto in lagu daweeyo noocyada kansarka dhiigga qaarkood. Inkasta oo ay tahay hab rajo leh oo awood leh, daraasado badan iyo tijaabooyin caafimaad ayaa loo baahan yahay si loo hagaajiyo loona helo habab cusub oo loo isticmaalo. Daaweynta CAR T-cell waxay bedeli kartaa sida loo daweeyo kansarka oo wax u roonaan kara dadka adduunka oo dhan haddii ay sii fiicnaanayso.
Yaa U Qalma Daawaynta Unugyada CAR T gudaha Singapore?
Singapore gudaheeda, u-qalmitaanka CAR T Therapy Cell waa mid xulasho ah oo loogu talagalay waxtarka ugu sarreeya.
Bukaannada xaqa u leh waa carruur iyo dhallinyaro qaan-gaar ah (3-25 jir) qaba unugyada B-unugyada Acute Lymphoblastic Leukemia (ALL) kuwaas oo dib u soo noqday tallaalka ka dib.
CAR T Therapy sidoo kale waxaa heli kara dadka waaweyn ee qaba Diffuse Large B-cell Lymphoma (DLBCL) kuwaas oo aan ka jawaabin ugu yaraan laba daawaynta caadiga ah.
Si kastaba ha ahaatee, kooxaha bukaanada qaarkood ma buuxin karaan shuruudaha u-qalmitaanka, oo ay ku jiraan kuwa qaba hypertension intracranial ama miyir la'aan, neefsashada oo xumaada, faafinta xinjirowga xididdada dhiigga, hematosepsis, ama caabuq firfircoon oo aan la xakameynin iyo sonkorowga. Xulashada taxaddarka leh ee bukaannada xaqa u leh waxay hubisaa in CAR T Therapy la siiyo shakhsiyaadka sida ugu badan uga faa'iideysan doona, kordhinta suurtagalnimada natiijooyinka daawaynta wanaagsan.
CAR T-Cell Therapy Oo Ay Ansixisay USFDA
KYMRIAH
Unugyada B-unugyada leukemia ba'an oo soo noqnoqda ama soo noqnoqda
Heerka jawaabta oo dhammaystiran (CR): >90%
Beegsiga: CD19
Price: $ 475,000
Waqtiga ansixinta: Agoosto 30, 2017
YESCARTA
Soo noqoshada ama dib-u-soo-celinta waxay kala firdhisaa lymphoma unugga B-weyn, soo noqoshada ama dib-u-kicinta unugyada follicular
Heerka jawaab celinta dhamaystiran ee lymphoma non-Hodgkin (CR): 51%
Beegsiga: CD19
Price: $ 373,000
Waqtiga ansixinta: 2017 Oktoobar 18
TECARTUS
Soo noqoshada ama dib-u-celinta waxay faafisaa lymphoma weyn ee unugyada B
Hoos waxaa ku yaal qaar ka mid ah waxyeelada daawaynta CAR T-cell.
Cytokine release syndrome (CRS): The most prevalent and possibly significant side effect of CAR T-cell treatment is cytokine release syndrome (CRS). The flu-like symptoms, including fever, exhaustion, headaches, and muscle pain, are brought on by the modified T cells’ production of cytokines. In extreme circumstances, CRS may result in a high temperature, hypotension, organ failure, and even potentially fatal consequences.
Sunta Neerfaha: Bukaanjiifka qaarkood waxaa laga yaabaa inay yeeshaan saameynaha neerfaha, kuwaas oo u dhexeeya darnaan laga bilaabo calaamado aan halis ahayn sida jahawareer khafiif ah iyo jahawareer ilaa kuwa ka sii daran sida suuxdin, delirium, iyo encephalopathy. Ka dib faleebada CAR T-cell, sunta neerfaha waxay badanaa dhacdaa usbuuca ugu horreeya.
Cytopenia: Daawaynta CAR T-cell waxay keeni kartaa inay hoos u dhigto tirooyinka unugyada dhiigga, sida dhiig-yarida (tirada unugyada dhiigga cas oo hooseeya), neutropenia (tirada unugyada dhiigga cad oo hooseeya), iyo thrombocytopenia (tirada platelet hoose). Caabuqyada, dhiig-baxa, iyo daalka ayaa ka mid ah khataraha ay uga sii dari karto cytopenia.
Caabuqyada: CAR T-cell therapy's xakamaynta unugyada difaaca jirka ee caafimaadka qaba waxay kordhisaa halista caabuqyada bakteeriyada, fayraska, iyo fungal. Si looga hortago infekshannada, bukaanku waxay u baahan karaan in si dhow loola socdo oo la siiyo daawo ka hortag ah.
Tumor Lysis Syndrome (TLS): After CAR T-cell therapy, it’s possible in some circumstances for substantial amounts of cell contents to be released into the bloodstream due to the rapid killing of buro cells. This may result in metabolic abnormalities, such as excessive potassium, uric acid, and phosphate levels, which may damage the kidneys and cause other problems.
Hypogammaglobulinemia: Daawaynta CAR T-cell waxay leedahay awood ay ku yarayso isku-darka unugyada difaaca jirka, taas oo keeni karta hypogammaglobulinemia. Tani waxay ka dhigi kartaa infekshannada soo noqnoqda inay u badan tahay waxayna wacdaa in la sii wado daawada beddelka unugyada.
Sunta Xubinta: Daaweynta CAR T-cell waxay leedahay awood ay ku waxyeeleyso tiro xubno ah, oo ay ku jiraan wadnaha, sambabada, beerka, iyo kelyaha. Tani waxay u horseedi kartaa baaritaanada shaqada kelyaha ee aan caadiga ahayn, arrimaha neefsashada, arrimaha wadnaha, iyo baaritaanka shaqada beerka ee aan caadiga ahayn.
Hemophagocytic lymphohistiocytosis (HLH): Cudur naadir ah laakiin suurtagal ah oo dilaa ah oo loo yaqaan hemophagocytic lymphohistiocytosis (HLH) ayaa ku soo bixi kara natiijada daawaynta CAR T-cell. Waxay ku lug leedahay firfircoonida xad-dhaafka ah ee unugyada difaaca jirka, taas oo keenta dhaawac halis ah xubnaha iyo bararka.
Hypotension iyo Haysashada Dheecaannada: Natiijadu waxay tahay cytokines ay unugyada CAR T sii daayaan, bukaannada qaarkood waxaa laga yaabaa inay yeeshaan cadaadis dhiig oo hooseeya (hypotension) iyo xajinta dareeraha. Si wax looga qabto calaamadahan, tillaabooyin taageero ah oo ay ku jiraan dheecaannada xididka iyo dawooyinka ayaa loo baahan karaa.
Xannaanada Labaad: Warbixinnada malignancies-ka labaad ee soo baxaya ka dib daaweynta CAR T-cell ayaa jira, inkastoo ay naadir yihiin. Cilmi baaris ayaa hadda lagu sameynayaa suurtagalnimada malignant-ka labaad iyo khataraha mustaqbalka fog.
Waxaa muhiim ah in la xasuusnaado in bukaan kastaa aanu yeelanayn waxyeellooyinkan iyo in qof walba heerka dareenkiisu uu kala duwanaan doono. Si loo yareeyo loona yareeyo saamaynta xun ee iman karta, kooxda caafimaadku waxay si dhow u baadhaan bukaanka ka hor, inta lagu jiro, iyo ka dib daawaynta CAR T-cell.
Waqtiga waqtiga
Hoos ka hubi wadarta wakhtiga loo baahan yahay si loo dhamaystiro habka daawaynta CAR T-Cell. Si kastaba ha ahaatee, waqtiga xaddidan wuxuu aad ugu xiran yahay masaafada shaybaarka u jiro isbitaalka diyaariyey CAR-yada.
Imtixaan & imtixaan: hal usbuuc
Daawaynta kahor & Ururinta T-Cell: hal usbuuc
Diyaarinta T-Cell & soo celinta: laba ilaa saddex toddobaad
Falanqaynta waxtarka 1aad: saddex toddobaad
2nd Waxtarka falanqaynta: saddex toddobaad.
Wadarta wakhtiga: 10-12 toddobaad
Sideen kuugu caawin karnaa inaad Singapore ka hesho daaweynta unug ee CAR T ee ugu fiican?
Helitaanka daawaynta saxda ah ee CAR-T ee Singapore way adkaan kartaa, laakiin anaga haddaan nahay Fakis Kansarka waxaan halkan u joognaa inaan ku caawinno tallaabo kasta oo aad waddo. Waxaan fahamsanahay sida uu muhiimka u yahay caafimaadkaaga, iyo in la huro tayada daryeelka ma aha ikhtiyaar. Waxaan dhisnay xiriirro dhakhaatiir xirfad sare leh waxaana la kaashanay dhowr isbitaal oo sumcad leh si aan kuu siino xulasho qiimo dhimis ah oo ku habboon baahiyahaaga, si la mid ah saaxiib la aamini karo. Hadafkayagu waa inaanu kaa caawino inaad hesho daawaynta unug ee CAR T-ga ugu fiican adoon culays saarayn dhaqaalahaaga. Habkayaga dhamaystiran ee daryeelka kansarka ayaa horeba u taageeray bukaanno ka kala yimid dalal kala duwan. nagu kalsoonow inaan ku hago oo aan hubino inaad hesho daawaynta ugu fiican ee suurtogalka ah si aad ula dagaallanto kansarka oo aad dhakhso u bogsato.
Waxaan u isticmaalnaa cookies-ka boggayaga si aan kuu siino waayo-aragnimada ugu habboon anagoo xasuusnaane waxaad door bidday iyo booqashooyinka soo noqnoqday. Adigoo gujinaya "Aqbal", waxaad ogolaanaysaa isticmaalka DHAMMAAN cookies-ka.
Websaydhkan wuxuu adeegsadaa cookies si uu u wanaajiyo khibradaada intaad dhex mareyso websaydhka. Baakadahaas ka baxsan, cookies-ka loo cayimay inay lagama maarmaan tahay ayaa lagu keydiyaa biraawsarkaaga maadaama ay muhiim u yihiin ka shaqeynta howlaha aasaasiga ah ee websaydhka. Waxaan kaloo isticmaalnaa cookies-yada seddexaad ee naga caawiya falanqaynta iyo fahamka sida aad u isticmaasho degelkan. Kukiyadahan waxaa lagu keydin doonaa biraawsarkaaga kaliya oggolaanshahaaga. Waxa kale oo aad ikhtiyaar u leedahay inaad ka baxdo cookies-ka. Laakiin ka bixitaanka qaar ka mid ah cookies-yadaas waxay saameyn ku yeelan karaan khibradahaaga biraawsarka.
Kukiyada aan loo baahnayn waa gebi ahaan muhiim u ah shabakadda si ay u shaqeyso si sax ah. Qeybtaan waxaa ku jira kaliya cookies si loo hubiyo hawlaha aasaasiga ah iyo astaamaha ammaanka ee bogga internetka. Kukiyadaasi ma kaydiso wax macluumaad shakhsi ah.
Kukooyin kasta oo aan laga maarmi karin gaar ahaan bogga internetka si loo shaqeeyo oo loo isticmaalo si gaar ah si loo ururiyo macluumaadka shakhsi ahaaneed ee macluumaadka shakhsiyeed iyadoo la adeegsanayo falanqaynta, xayeysiisyada, waxyaabaha kale ee loo adeegsaday ayaa loo yaqaan 'cookies unnecessary'. Waa qasab in aad soo iibsato ogolaanshaha isticmaalka ka hor intaadan ku dhicin cookies-kaaga boggaaga.
Bilow sheekada
Waxaan nahay Online! Nala hadal!
Sawir koodka
Hello,
Ku soo dhawoow CancerFax!
CAR T daawaynta unug ee Singapore waxay ku kacaysaa inta u dhaxaysa 450,000 iyo 500,000 USD, taas oo ku xidhan nooca iyo heerka cudurka iyo cisbitaalka la doortay.
Fadlan noo soo dir warbixinnadaada caafimaad, waxaanan kugu soo celin doonaa faahfaahinta daaweynta, isbitaalka, iyo qiyaasta kharashka.
